Published in Hypertension on July 18, 2016
The biology of vascular endothelial growth factor. Endocr Rev (1997) 13.70
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med (2003) 6.09
Sepsis definitions: time for change. Lancet (2013) 5.63
Novel strategies for the treatment of sepsis. Nat Med (2003) 5.14
Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol Rev (1992) 4.56
HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest (2001) 4.11
Decreased number and impaired angiogenic function of endothelial progenitor cells in patients with chronic renal failure. Arterioscler Thromb Vasc Biol (2004) 1.78
Inflammation, immunity, and hypertensive end-organ damage. Circ Res (2015) 1.77
Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation (2005) 1.75
Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3beta pathway. Cardiovasc Res (2008) 1.67
Is hypertension an inflammatory disease? Med Hypotheses (2005) 1.64
BCL2 genetic variants are associated with acute kidney injury in septic shock*. Crit Care Med (2012) 1.61
Forkhead homeobox type O transcription factors in the responses to oxidative stress. Antioxid Redox Signal (2010) 1.59
Kallistatin is a new inhibitor of angiogenesis and tumor growth. Blood (2002) 1.54
Kallistatin, a novel human tissue kallikrein inhibitor: levels in body fluids, blood cells, and tissues in health and disease. J Lab Clin Med (1996) 1.48
Molecular mechanisms of hypertension--reactive oxygen species and antioxidants: a basic science update for the clinician. Can J Cardiol (2012) 1.36
Kallistatin: a novel human tissue kallikrein inhibitor. Purification, characterization, and reactive center sequence. J Biol Chem (1992) 1.34
Nitric oxide inactivates NADPH oxidase in pig neutrophils by inhibiting its assembling process. J Biol Chem (1997) 1.33
Role of the NADPH oxidases in the subfornical organ in angiotensin II-induced hypertension. Hypertension (2012) 1.33
Prophylactic adenovirus-mediated human kallistatin gene therapy suppresses rat arthritis by inhibiting angiogenesis and inflammation. Arthritis Rheum (2005) 1.31
Salutary effect of kallistatin in salt-induced renal injury, inflammation, and fibrosis via antioxidative stress. Hypertension (2008) 1.28
Emerging avenues linking inflammation and cancer. Free Radic Biol Med (2012) 1.28
Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J Leukoc Biol (1998) 1.26
Role of kallistatin in prevention of cardiac remodeling after chronic myocardial infarction. Lab Invest (2008) 1.25
Novel role of kallistatin in protection against myocardial ischemia-reperfusion injury by preventing apoptosis and inflammation. Hum Gene Ther (2006) 1.23
Structural elements of kallistatin required for inhibition of angiogenesis. Am J Physiol Cell Physiol (2003) 1.20
Pharmacological approaches to improve endothelial repair mechanisms. Expert Rev Cardiovasc Ther (2008) 1.20
SOCS, inflammation, and cancer. JAKSTAT (2013) 1.13
Tissue kallikrein-binding protein is a serpin. I. Purification, characterization, and distribution in normotensive and spontaneously hypertensive rats. J Biol Chem (1990) 1.13
Kallistatin inhibits vascular inflammation by antagonizing tumor necrosis factor-alpha-induced nuclear factor kappaB activation. Hypertension (2010) 1.12
Kallistatin attenuates endothelial apoptosis through inhibition of oxidative stress and activation of Akt-eNOS signaling. Am J Physiol Heart Circ Physiol (2010) 1.11
Kallistatin: a novel human serine proteinase inhibitor. Molecular cloning, tissue distribution, and expression in Escherichia coli. J Biol Chem (1993) 1.11
Depletion of endogenous kallistatin exacerbates renal and cardiovascular oxidative stress, inflammation, and organ remodeling. Am J Physiol Renal Physiol (2012) 1.10
Tissue kallikrein in cardiovascular, cerebrovascular and renal diseases and skin wound healing. Biol Chem (2010) 1.10
Kruppel-like factor 4 is a novel mediator of Kallistatin in inhibiting endothelial inflammation via increased endothelial nitric-oxide synthase expression. J Biol Chem (2009) 1.09
Identification of a major heparin-binding site in kallistatin. J Biol Chem (2001) 1.08
Identification of a new tissue-kallikrein-binding protein. Biochem J (1986) 1.08
Localization and expression of tissue kallikrein and kallistatin in human blood vessels. J Histochem Cytochem (1999) 1.07
Beneficial effects of kallikrein-binding protein in transgenic mice during endotoxic shock. Life Sci (1997) 1.07
Plasma kallistatin levels in patients with severe community-acquired pneumonia. Crit Care (2013) 1.07
Endothelial progenitor cells: therapeutic target for cardiovascular diseases. J Pharmacol Sci (2008) 1.04
Kallikrein-binding protein inhibits retinal neovascularization and decreases vascular leakage. Diabetologia (2003) 1.03
Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res (1998) 1.03
The role of endothelial-mesenchymal transition in development and pathological process. IUBMB Life (2012) 1.00
Kallistatin is a potent new vasodilator. J Clin Invest (1997) 0.99
SERPINA3K prevents oxidative stress induced necrotic cell death by inhibiting calcium overload. PLoS One (2008) 0.96
βII-Spectrin (SPTBN1) suppresses progression of hepatocellular carcinoma and Wnt signaling by regulation of Wnt inhibitor kallistatin. Hepatology (2015) 0.95
Biochemistry, regulation and potential function of kallistatin. Biol Chem Hoppe Seyler (1995) 0.95
Circulating endothelial progenitor cells inversely associate with organ dysfunction in sepsis. Intensive Care Med (2012) 0.95
Kallikrein-binding protein inhibits growth of gastric carcinoma by reducing vascular endothelial growth factor production and angiogenesis. Mol Cancer Ther (2007) 0.94
Inhibition of angiogenesis and HCT-116 xenograft tumor growth in mice by kallistatin. World J Gastroenterol (2007) 0.93
Roles of the P1, P2, and P3 residues in determining inhibitory specificity of kallistatin toward human tissue kallikrein. J Biol Chem (2000) 0.93
Kallistatin antagonizes Wnt/β-catenin signaling and cancer cell motility via binding to low-density lipoprotein receptor-related protein 6. Mol Cell Biochem (2013) 0.93
Kallistatin in human ocular tissues: reduced levels in vitreous fluids from patients with diabetic retinopathy. Curr Eye Res (1996) 0.92
Antiangiogenic and antineuroinflammatory effects of kallistatin through interactions with the canonical Wnt pathway. Diabetes (2013) 0.92
Kallikrein and kinin receptor genes. Pharmacol Ther (2000) 0.91
Adeno-associated virus-mediated expression of kallistatin suppresses local and remote hepatocellular carcinomas. J Gene Med (2008) 0.91
Pivotal role of JNK-dependent FOXO1 activation in downregulation of kallistatin expression by oxidative stress. Am J Physiol Heart Circ Physiol (2010) 0.90
Kallikrein-binding protein levels are reduced in the retinas of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci (1997) 0.90
Upregulation of kallistatin expression in rheumatoid joints. J Rheumatol (2007) 0.89
Adenovirus-mediated delivery of human kallistatin gene reduces blood pressure of spontaneously hypertensive rats. Hum Gene Ther (1997) 0.89
Kallistatin modulates immune cells and confers anti-inflammatory response to protect mice from group A streptococcal infection. Antimicrob Agents Chemother (2013) 0.88
Reactive-site specificity of human kallistatin toward tissue kallikrein probed by site-directed mutagenesis. Biochim Biophys Acta (2000) 0.88
Plasma kallistatin is associated with adiposity and cardiometabolic risk in apparently healthy African American adolescents. Metabolism (2012) 0.88
Protection effect of kallistatin on carbon tetrachloride-induced liver fibrosis in rats via antioxidative stress. PLoS One (2014) 0.87
Cellular localization of tissue kallikrein and kallistatin mRNAs in human kidney. Kidney Int (1995) 0.87
Inhibition of experimental lung metastasis by systemic lentiviral delivery of kallistatin. BMC Cancer (2010) 0.87
Increased serum kallistatin levels in type 1 diabetes patients with vascular complications. J Angiogenes Res (2010) 0.87
SERPINA3K induces apoptosis in human colorectal cancer cells via activating the Fas/FasL/caspase-8 signaling pathway. FEBS J (2013) 0.87
Expression of kallikrein-binding protein and alpha 1-antitrypsin genes in response to sex hormones, growth, inflammation and hypertension. Agents Actions Suppl (1992) 0.86
Human kallistatin administration reduces organ injury and improves survival in a mouse model of polymicrobial sepsis. Immunology (2014) 0.86
In vivo catabolism of human kallikrein-binding protein and its complex with tissue kallikrein. J Lab Clin Med (1992) 0.85
Kallistatin, a novel anti-angiogenesis agent, inhibits angiogenesis via inhibition of the NF-κB signaling pathway. Biomed Pharmacother (2014) 0.85
Molecular cloning and analysis of the rat kallikrein-binding protein gene. J Biol Chem (1991) 0.85
Combining kallistatin gene therapy and meloxicam to treat hepatocellular carcinoma in mice. Cancer Sci (2009) 0.85
Kallistatin protects against sepsis-related acute lung injury via inhibiting inflammation and apoptosis. Sci Rep (2015) 0.84
Kallistatin induces breast cancer cell apoptosis and autophagy by modulating Wnt signaling and microRNA synthesis. Exp Cell Res (2016) 0.84
Circulating endothelial progenitor cells: a new approach to anti-aging medicine? J Transl Med (2009) 0.84
A major difference of kallikrein-binding protein in spontaneously hypertensive versus normotensive rats. J Hypertens (1988) 0.84
Altered protein expression at early-stage rat hepatic neoplasia. Am J Physiol Gastrointest Liver Physiol (2007) 0.83
Kallistatin inhibits TGF-β-induced endothelial-mesenchymal transition by differential regulation of microRNA-21 and eNOS expression. Exp Cell Res (2015) 0.83
Differential interactions of human kallikrein-binding protein and alpha 1-antitrypsin with human tissue kallikrein. Biochem J (1990) 0.82
Novel role of kallistatin in vascular repair by promoting mobility, viability, and function of endothelial progenitor cells. J Am Heart Assoc (2014) 0.82
Intramuscular delivery of rat kallikrein-binding protein gene reverses hypotension in transgenic mice expressing human tissue kallikrein. J Biol Chem (1995) 0.82
Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats. Am J Physiol (1996) 0.82
Intestinal tissue kallikrein-kallistatin profile in inflammatory bowel disease. Int Immunopharmacol (2003) 0.81
SERPINA3K protects against oxidative stress via modulating ROS generation/degradation and KEAP1-NRF2 pathway in the corneal epithelium. Invest Ophthalmol Vis Sci (2012) 0.81
Elevated circulation levels of an antiangiogenic SERPIN in patients with diabetic microvascular complications impair wound healing through suppression of Wnt signaling. J Invest Dermatol (2014) 0.81
Kallikrein-binding protein suppresses growth of hepatocellular carcinoma by anti-angiogenic activity. Cancer Lett (2007) 0.81
Kallistatin treatment attenuates lethality and organ injury in mouse models of established sepsis. Crit Care (2015) 0.81
Effects of antioxidants and nitric oxide on TNF-alpha-induced adhesion molecule expression and NF-kappaB activation in human dermal microvascular endothelial cells. Life Sci (2004) 0.81
Tissue kallikrein-binding protein reduces blood pressure in transgenic mice. J Biol Chem (1996) 0.81
Role of Inflammation and Immunity in Hypertension: Recent Epidemiological, Laboratory, and Clinical Evidence. Curr Hypertens Rep (2016) 0.81
Molecular cloning, sequence analysis, and chromosomal localization of the human protease inhibitor 4 (kallistatin) gene (PI4). Genomics (1994) 0.80
Kallikrein-binding protein inhibits LPS-induced TNF-α by upregulating SOCS3 expression. J Cell Biochem (2013) 0.80
Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin. Antimicrob Agents Chemother (2015) 0.78
Molecular cloning and sequence analysis of the mouse kallikrein-binding protein gene. Biochim Biophys Acta (1991) 0.77
SERPINA3K plays antioxidant roles in cultured pterygial epithelial cells through regulating ROS system. PLoS One (2014) 0.77
Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis. Acta Pharm Sin B (2015) 0.76